| Article
In a first of its kind clinical—and randomized, double-blind, placebo-controlled—trial, migraine sufferers will be given, via a vaporizer, CBD, THC, CBD and THC, and a placebo for 4 separate migraine attacks. Participants, ages 21 to 65, will self-administer as early as possible at the start of a...
| Article
In an article in the Canadian Journal of Anaesthesia, researchers investigated patients attempting to get medical cannabis for their chronic pain. Researchers looked at the long-term effect of cannabis on these patients through patterns of cannabis use and primary outcomes—pain intensity and...
| Article
Bracing statistics from the journal Addiction show that medical marijuana to combat chronic pain has, for some patients, negative consequences. In a group of 527 people—82% white, 49% male, average age 45.6 years—looking to be certified or recertified for medical marijuana it was found that over 40%...
| Article
The American Heart Association has issued a scientific statement calling for education for clinicians on the health implications of cannabis products. They are calling for funding and clinical trials, both of which are predicated on the removal of legal hurdles. The AHA states, “Our understanding of...
| Article
Newswise — Medical cannabis is finally being put under the microscope, in a first-of-its-kind real world evidence study led by Dr. Hance Clarke, Director of Pain Services, Toronto General Hospital, and a recognized leader in educating Canadians about chronic pain management and the risk factors of...
| Article
From the European Journal of Pain.
Background: Precise cannabis treatment dosing remains a major challenge, leading to physicians’ reluctance to prescribe medical cannabis.
Objective: To test the pharmacokinetics, analgesic effect, cognitive performance and safety effects of an innovative...
| Video
The prescribing of chronic opioid therapy to patients who contemplate or are already using marijuana, whether medical or recreational, sets up the perfect storm for medical decision-making and risk management conundrums, especially in the current environment of opioid related hospital admissions and...
| Article
Newswise — More than 90% of the legal marijuana products offered in medical dispensaries are much stronger than what clinical studies have shown that doctors recommend for chronic pain relief, according to a study published in the March 26 online edition of the journal PLOS ONE.
To many that...
| Video
Despite the widespread acceptance of medicinal and recreational cannabis use internationally and domestically, marijuana remains federally illegal in the United States. For this reason, there are significant legal implications to clinical practice. But what about endocannabinoid deficiency syndrome...
| Article
Newswise — McMaster University researchers have identified an antibacterial compound made by cannabis plants that may serve as a lead for new drug development.
An interdisciplinary team of McMaster researchers found that the chemical compound, or cannabinoid, called cannabigerol (CBG) is not only...